Which therapy would be best to regain control in an adult patient still experiencing asthma exacerbations despite increased reliever therapy?

Rationale: A. Systemic corticosteroids such as prednisone are the gold standard for managing acute asthma exacerbations that fail to respond to intensified rescue therapy. A 5 day burst of 40 mg daily effectively suppresses the underlying airway inflammation and reduces the risk of relapse or hospitalization. This intervention addresses the biological root of the exacerbation rather than just providing temporary bronchodilation. B. Increasing the frequency of beta 2 agonists provides only transient relief of bronchospasm without addressing the progressive inflammatory cascade occurring during an exacerbation. Over-reliance on these rescue agents is associated with increased mortality and downward regulation of beta-receptors, making the medication less effective over time. It does not provide the anti-inflammatory power needed to regain long-term clinical control. C. While montelukast is a maintenance treatment that blocks leukotriene receptors, it has a slow onset of action and is insufficient for treating an acute, worsening exacerbation. It is typically used as an add-on therapy for chronic management rather than a rescue or "burst" intervention. Using it in this context would delay the necessary administration of more potent systemic anti-inflammatory agents. D. Doubling the dose of a maintenance inhaled corticosteroid is no longer recommended as an effective strategy for managing acute asthma worsening in adults. Clinical trials have demonstrated that this approach does not significantly reduce the need for oral corticosteroids or prevent severe exacerbation progression. A distinct course of oral steroids is required to achieve the systemic concentration necessary for rapid recovery.